TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00533702
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
Study: NCT02701127
Drug: Oral niacinamide, 1 gram daily
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02701127
Drug: Oral niacinamide, 3 gram daily
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04113954
Drug: Mepivacaine Injection
Normalized name: mepivacaine Injection
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 0.375% mepivacaine in nerve block
Study: NCT04113954
Drug: Mepivacaine Injection
Normalized name: mepivacaine Injection
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 1.5% mepivacaine in nerve block
Study: NCT04247659
Drug: sodium aescinate
Normalized name: sodium aescinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.
Study: NCT04859582
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as an IV infusion on Day 1 Q3W
Study: NCT04859582
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as a continuous IV infusion on Days 1-5 Q3W
Study: NCT04859582
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as an IV infusion on Day 1 Q3W
Study: NCT04859582
Drug: Placebo for Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as an IV infusion on Day 1 Q3W
Study: NCT02277743
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
Study: NCT02522104
Drug: Siklos
Normalized name: Siklos
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02055157
Drug: BMN 111
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
Study: NCT03783936
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m2
Study: NCT03783936
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1
Study: NCT03783936
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 800 mg
Study: NCT02592538
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if \<1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.
Study: NCT00967382
Drug: dalteparin sodium
Normalized name: Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum
Study: NCT02010632
Drug: Generic clopidogrel product Apolets®
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7
Study: NCT02010632
Drug: Original clopidogrel product Plavix®
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7
Study: NCT02013492
Drug: propranolol hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01092481
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
Study: NCT03907163
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules containing 5 mg Dronabinol
Study: NCT00853502
Drug: testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
Study: NCT01208740
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg three times daily
Study: NCT03877965
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses
Study: NCT00892489
Drug: ER OROS Paliperidone
Normalized name: paliperidone Extended Release Oral Tablet
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03054038
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by mouth
Study: NCT02915094
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00474045
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treat-to-target, dose titration, s.c. (under the skin) injection
Study: NCT01737346
Drug: lomustine and procarbazine
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
Study: NCT01054261
Drug: avanafil
Normalized name: Avanafil
DrugBank: Avanafil (DB06237)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg avanafil tablet QD
Study: NCT03345979
Drug: Paliperidone Palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular injection
Study: NCT00474045
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treat-to-target, dose titration, s.c. (under the skin) injection
Study: NCT03033316
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01082562
Drug: BMS-844421
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days
Study: NCT01082562
Drug: 0.9% sodium chloride injection solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection solution, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days
Study: NCT00367965
Drug: Eszopiclone
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eszopiclone 3 mg
Study: NCT02407899
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take saxagliptin tablet 5mg p.o. qd. for 104 weeks after randomization.
Study: NCT02407899
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take vitamin D drops 2000 IU p.o. qd. for 104 weeks after randomization.
Study: NCT02407899
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
Study: NCT02407899
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Take Metformin tablet 1.5g p.o. per day for 104 weeks (adjust the dose between 1-1.7g per day according to subject's specific situation) before or after randomization.
Study: NCT02266472
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single dose of metformin given as tablets
Study: NCT02266472
Drug: empagliflozin/metformin
Normalized name: EMPAGLIFLOZIN/METFORMIN
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose empagliflozin/metformin given as fixed-dose combination tablet
Study: NCT02266472
Drug: empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single dose of empagliflozin given as tablet
Study: NCT00808639
Drug: vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenously 3mg/m2 over 30 minutes
Study: NCT00808639
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
Study: NCT00808639
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given subcutaneously 24 hours after last chemotherapy dose
Study: NCT03088046
Drug: Micronized Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anovulatory women with Polycystic ovary syndrome and clinical hyperandrogenism attended in our Hospital will participate in the study. A patient information sheet will be provided and written consent will be obtained. Patients who give written consent will participate in the trial. All patient information will be confidential and only be available to researches involved in the study.~Blood samples will be collected at baseline (Sample #1) and between the 3rd and the 5th day of withdrawal after 7 days of 100mg vaginal MP every 12 hours of administration(Sample#2).
Study: NCT03053063
Drug: SEL
Normalized name: Selen
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT03197324
Drug: Bexagliflozin
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin tablets, 20 mg
Study: NCT03197324
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)
Study: NCT01151202
Drug: AG NPP709syrup
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00020943
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg/kg IV infusion over 2 hours Day 6, Tx 4
Study: NCT00020943
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3
Study: NCT00020943
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3
Study: NCT00020943
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/sq m PO Days 3-7, Tx 1 \& 2
Study: NCT00020943
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/sq m IVP Day 3, Tx 1 \& 2
Study: NCT00004406
Drug: human parathyroid hormone
Normalized name: 1-36 human parathyroid hormone-related protein
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03202381
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~* Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~* Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression.
Study: NCT03002064
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
Study: NCT03002064
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
Study: NCT01585753
Drug: NRTI + PI
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
Study: NCT01585753
Drug: maraviroc + PI
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir
Study: NCT01585753
Drug: maraviroc + NRTI
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine
Study: NCT01717482
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03400176
Drug: ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Approved medication
Study: NCT02074228
Drug: Methylphenidate (Concerta)
Normalized name: methylphenidate Extended Release Oral Tablet [Concerta]
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04443062
Drug: 177Lu-PSMA-617
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSMA radioligand therapy
Study: NCT00102531
Drug: Cisplatin liposomal
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02736188
Drug: Aceneuramic Acid Extended-Release Tablets
Normalized name: aceneuramic acid
DrugBank: Aceneuramic acid (DB11797)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03755115
Drug: Epirubicin plus SHR1210
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First intravenous injection of epirubicin injection, D1,30mg/m\^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, 30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m\^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
Study: NCT01698918
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
Study: NCT01698918
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued
Study: NCT01698918
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued
Study: NCT01698918
Drug: Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).
Study: NCT04989127
Drug: Analgesic
Normalized name: Analgesic
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analgesics are prescribed for the patients.
Study: NCT04989127
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with penicillin allergy
Study: NCT00288067
Drug: fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00288067
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00954512
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00954512
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00954512
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00954512
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00954512
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00954512
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00954512
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00954512
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00954512
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00954512
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00246233
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00859651
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each.
Study: NCT02409563
Drug: Budesonide nasal spray (100 mcg bid)
Normalized name: budesonide Nasal Spray
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00444041
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: neoadjuvant therapy prior to elective surgery
Study: NCT01255800
Drug: IPI-926 and Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Patients will receive Cetuximab IV every week.~* Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day.
Study: NCT02234596
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.
Study: NCT00073983
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel
Study: NCT00073983
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine hydrochloride
Study: NCT00129922
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00129922
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00963027
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will receive a single 40 mg capsule of esomeprazole by mouth in the morning for seven days.
Study: NCT00639574
Drug: Néfopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are two groups :~* a group N : néfopam~* a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes.
Study: NCT00670488
Drug: MK-2206
Normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
Study: NCT03726294
Drug: NBM-BMX softgel capsules
Normalized name: docusate sodium Oral Capsule [Correctol Softgel Extra Gentle]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will initially receive NBM-BMX orally once a day at 100 mg per day.